Previous Article | Next Article ![]()
Mol. Cell. Biol., 03 1995, 1302-1311, Vol 15, No. 3
JA DiDonato, F Mercurio and M Karin
NF-kappa B is an important activator of immune and inflammatory response
genes. NF-kappa B is sequestered in the cytoplasm of nonstimulated cells
through interaction with the I kappa B inhibitors. These inactive complexes
are dissociated in response to a variety of extracellular signals, thereby
allowing free NF-kappa B dimers to translocate to the nucleus and active
transcription of specific target genes. The current dogma is that
phosphorylation of the I kappa Bs is responsible for dissociation of the
inactive complexes, an event that is rendered irreversible by rapid I kappa
B degradation. Here, we show that inducers of NF-kappa B activity stimulate
the hyperphosphorylation of one of the I kappa Bs, I kappa B alpha.
However, contrary to the present dogma the hyperphosphorylated form of I
kappa B alpha remains associated with NF-kappa B components such as RelA
(p65). Thus, phosphorylation of I kappa B alpha is not sufficient to cause
dissociation of the inactive NF-kappa B:I kappa B alpha complex. However,
that complex is disrupted through the selective degradation of
phosphorylated I kappa B alpha in response to extracellular signals. Using
a variety of protease inhibitors, some of which have specificity towards
the multicatalytic proteinase complex, we demonstrate that degradation of I
kappa B alpha is required for NF-kappa B activation. The results of these
experiments are more consistent with a new model according to which
phosphorylation of I kappa B alpha associated with NF-kappa B marks it for
proteolytic degradation. I kappa B alpha is degraded while bound to
NF-kappa B. The selective degradation of I kappa B alpha releases active
NF-kappa B dimers which can translocate to the nucleus to activate specific
target genes.
Copyright © 1995, American Society for Microbiology
Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B
Department of Pharmacology, University of California, San Diego School of Medicine, La Jolla 92093-0636.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|